Method and arrangement for determination of the individual incretin sensitivity index of a subject

• US 20100312485A1
• Filed: 06/07/2010
• Published: 12/09/2010
• Est. Priority Date: 06/08/2009
• Status: Abandoned Application

• Current Assignee: Eckhard Salzsieder, Petra Augstein
• Original Assignee: Eckhard Salzsieder, Petra Augstein
• Inventors: Salzsieder, Eckhard, Augstein, Petra
• Application Number:
  US12/802,434
• Publication Number:
  US 20100312485A1
• Time in Patent Office: Days
• US Class Current: 702/19
• CPC Class Codes: G16H 50/50 for simulation or modelling of medical disorders

Abstract

A computer-aided method for determination of a subject'"'"'s individual incretin sensitivity index determines the individual metabolic situation in the form of the personal metabolic situation of the subject. The individual incretin effect factor and the effect found of the administered incretin mimetic or incretin enhancer by simulation for the mean deviation of the daily glycemia are determined with the personal metabolic situation data and recorded numerically. The corresponding effect factor of a slow-acting insulin, whose step-by-step administration is varied until the mean deviation of the daily glycemia is identical to the mean deviation of the daily glycemia determined previously by the incretin mimetic or incretin enhancer, is determined. The insulin dosage is recorded numerically. The individual incretin sensitivity index is calculated from the relationship between the dosages of the incretin mimetic or incretin enhancer determined for identical deviation of the daily glycemia and the respectively individually different insulin dosage.

Claims

1. Method for determination of the individual incretin sensitivity index of a subject, preceded by computer-aided determination of the individual metabolic situation in the form of the personal metabolic situation of the subject, wherein with the data of the personal metabolic situation, the individual incretin effect factor and the established effect of the administered incretin mimetic are determined and recorded numerically by simulation for the mean deviation in the daily glycemia, and then the corresponding effect factor of a slow-acting insulin, whose step-by-step administration takes place until the mean deviation of the daily glycemia is identical to the mean deviation of the daily glycemia determined previously by the incretin mimetic or incretin enhancer, is determined, and the insulin dosage is recorded numerically, and the incretin sensitivity index is calculated from the relationship between the dosages of the incretin mimetic or incretin enhancer determined for identical deviation of the daily glycemia and the respectively individually different insulin dosage.

2. Method for determination of the individual incretin sensitivity index of a subject according to claim 1, wherein the method is carried out by means of automated in-silico simulation strategy.

3. Method for determination of the individual incretin sensitivity index of a subject according to claim 1, wherein the subject is considered to be sensitive to incretin if the value of the incretin sensitivity index is greater than 1.

4. Arrangement for determination of the individual incretin sensitivity index of a subject, wherein, on the input side, the arrangement comprises a first series circuit, in which the inputs of a data input module (1) for the data signal for the continuously measured daily glucose profile (CGM), the data signal for the subject base data (PBD) and the data signal for the self-monitoring data (SKD), a downstream anonymization and memory module (2) for allocation of the subject identity and for storage thereof in the patient data memory, an identification module (3) which produces the characteristic daily profile (CTP), to whose second input a model module (4) in which the mathematical model for describing the physiological glucose metabolism and the iteration program are stored, is coupled, and an incretin effect calculation module (5), to whose second input an incretin data input and memory module (5.1) which produces the data signal for the dosage of the incretin mimetic or incretin enhancer, is connected, are connected in series, wherein the output of the incretin effect calculation module, which generates the data signals for the daily glucose profile of the incretin effect (GTP_GLP) and the mean deviation of the blood glucose concentration for the incretin effect (MBG_GLP) are generated, is coupled to the first input of a comparator module (6), wherein an insulin data input and memory module (7.1), which produces the data signal for the insulin dosage, is connected upstream of the first input of an insulin effect calculation module (7), wherein, from the output of the insulin effect calculation module, the data signals generated by it for the daily glucose profile for the insulin effect (GTP_INS) and the mean deviation of the blood glucose concentration (MBG_INS) are applied to the second input of the comparator module, wherein the first output of the comparator module for the no decision is fed back for dosage equality of incretin and insulin via the insulin dose change module (8) to the second input of the insulin effect calculation module, wherein the input of an incretin effect equivalent calculation module (9) is connected to the second output of the comparator module for the yes decision for dosage equality of incretin and insulin, and its output produces the data signal for the daily glucose profile of the insulin effect profile (GTP_GLPequ), which is equivalent to the incretin effect, for the downstream calculation module for the incretin effect equivalent insulin dose (INS_equ) (10), wherein the output of the calculation module for the incretin effect equivalent insulin dose (INS_equ), which produces the data signal for the incretin effect equivalent insulin dose (INS_equ), is connected to the input of the incretin sensitivity index calculation module (11) in that the output of the incretin sensitivity index calculation module, which produces the data signal for the incretin sensitivity index (ISI), is connected to the input of the downstream output module for the incretin sensitivity index (12), and wherein the output module for the incretin sensitivity index, after its individual assessment of the incretin sensitivity index, as carried out by itself, produces at its output the data signal for the assessed incretin sensitivity index (ISI_B) as a process result of the automated insilico simulation strategy.